Lung cancer and pleural mesothelioma are often confused, so it’s important to understand the key differences between them, including tumor location and treatments. Lung cancer and pleural mesothelioma ...

Preclinical studies indicate that cavity-resident macrophages in the peritoneal and pleural spaces contribute to immunosuppression and cancer progression. While these macrophages typically accumulate ...

Understanding the nature of malignant effusions, teeming with tumor cells and clusters, is critical in comprehending the breadth of cancer's impact. The significant role of tumor clusters, with their ...

The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in ...

Visceral pleural invasion of non–small cell lung cancer (NSCLC) was investigated in this analysis for its potential to predispose patients to worse survival outcomes and greater chances of disease ...

In patients with small, peripheral non–small cell lung cancer (NSCLC), visceral pleural invasion leads to worse disease-free and recurrence-free survival as well as higher rates of recurrence, ...

To investigate their recruitment, Gata6-iCreER mice were crossed with Cd45-Dre and R26-tdT mice, enabling specific lineage tracing of cavity macrophages. Flow cytometry and immunofluorescence ...